Predictive factors of [18F]-Choline PET/CT in 170 patients with increasing PSA after primary radical treatment

Journal of Cancer Research and Clinical Oncology

Volumn 139, Issue 3, 2013, Pages 521-528

  Detti, Beatrice ^a   Scoccianti, Silvia ^a   Franceschini, Davide ^a   Cipressi, Samantha ^a   Cassani, Sara ^a   Villari, Donata ^b   Gacci, Mauro ^b   Pupi, Alberto ^a   Vaggelli, Luca ^a   Saieva, Calogero ^c   Pertici, Maurizio ^a   Livi, Lorenzo ^a   Ceroti, M ^c   Nicita, Giulio ^b   Carini, Marco ^b   Biti, Giampaolo ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c CANCER RESEARCH AND PREVENTION INSTITUTE ISPO   (Italy)

Author keywords

Choline PET CT; Prostate cancer; Prostatectomy; Radiotherapy

Indexed keywords

FLUOROCHOLINE F 18; HORMONE; PROSTATE SPECIFIC ANTIGEN; RADIOISOTOPE; UNCLASSIFIED DRUG; CHOLINE; DIAGNOSTIC AGENT; FLUORINE;

ADULT; AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC TEST ACCURACY STUDY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT REFERRAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY; ADJUVANT THERAPY; BLOOD; CARCINOMA; COHORT ANALYSIS; EVALUATION; METHODOLOGY; MIDDLE AGED; MORTALITY; PROGNOSIS; PROSTATE TUMOR; PROSTATECTOMY; SCINTISCANNING; SURVIVAL; UPREGULATION;

AGED; CARCINOMA; CHOLINE; COHORT STUDIES; FLUORINE RADIOISOTOPES; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; UP-REGULATION;

MLCS; MLOWN;

EID: 84876315706     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-012-1354-4     Document Type: Article

References (32)

1. Breeuwsma AJ, Pruim J, van den Bergh AC et al (2010) Detection of local, regional, and distant recurrence in patients with PSA relapse after external-beam radiotherapy using (11)C-Choline positron emission tomography. Int J Radiat Oncol Biol Phys 77:160-164
2. Castellucci P, Fuccio C, Nanni C, Santi I, Rizzello A, Lodi F et al (2009) Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy. J Nucl Med 50:1394-1400
3. Castellucci P, Fuccio C, Rubello D et al (2011) Is there a role for 11C-Choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml? Eur J Nucl Med Mol Imaging 38:55-63
4. Cimitan M, Bortolus R, Morassut S et al (2006) [(18)F] fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 33:1387-1398
5. Contractor K, Challapalli A, Barwick T, Winkler M, Hellawell G, Hazell S et al (2011) Use of [11C]Choline PET-CT as a noninvasive method for detecting pelvic lymph node status from prostate cancer and relationship with choline kinase expression. Clin Cancer Res 17:7673-7683
6. De Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ (2002) Visualization of prostate cancer with 11C-Choline positron emission tomography. Eur Urol 42:18-23
7. De Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ (2003a) Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-Choline PET. J Nucl Med 44:331-335
8. De Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ (2003b) 11C-Choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol 44:32-39
9. Effert PJ, Bares R, Handt S, Wolff JM, Bull U, Jakse G (1996) Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose. J Urol 155:994-998
10. Giovacchini G, Picchio M, Scattoni V et al (2010a) PSA doubling time for prediction of [(11)C] Choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging 37:1106-1116
11. Giovacchini G, Picchio M, Coradeschi E et al (2010b) Predictive factors of [(11)C]Choline PET/CT in patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging 37:301-309
12. Hara T, Kosada N, Kondo T, Kishi H, Kobori O (1997) Imaging of brain tumor, lung cancer, esophageal cancer, colon cancer, prostate cancer and bladder cancer with (C-11)Choline. J Nucl Med 38:250
13. Hara T, Kosaka N, Kishi H (1998) PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 39:990-995
14. Heinisch M, Dirisamer A, Loidl W et al (2006) Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml? Mol Imaging Biol 8:43-48
15. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics 2010. CA Cancer J Clin 60(5):277-300
16. Kotzerke J, Prang J, Neumaier B et al (2000) Experience with carbon-11 Choline positron emission tomography in prostate carcinoma. Eur J Nucl Med 27:1415-1419
17. Krause BJ, Souvatzoglou M, Tuncel M, Herrmann K, Buck AK, Praus C et al (2008) The detection rate of [11C]Choline-PET/TC depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 35:18-23
18. Liu IJ, Zafar MB, Lai YH, Segall GM, Terris MK (2001) Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology 57:108-111
19. Oyama N, Akino H, Suzuki Y et al (1999) The increased accumulation of [18F]fluorodeoxyglucose in untreated prostate cancer. Jpn J Clin Oncol 29:623-629
20. Pelosi E, Arena V, Skanjeti A, Pirro V, Douroukas A, Pupi A et al (2008) Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer. Radiol Med 113:895-904
21. Picchio M, Messa C, Landoni C et al (2003) Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F] fluorodeoxyglucose-positron emission tomography. J Urol 169:1337-1340
22. Picchio M, Briganti A, Fanti S, Heidenreich A, Krause BJ, Messa C et al (2011) The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. Eur Urol 59:51-60
23. Pinkawa M, Attieh C, Piroth MD, Holy R, Nussen S, Klotz J et al (2009) Dose-escalation using intensity-modulated radiotherapy for prostate cancer- evaluation of the dose distribution with and without 18F-choline PET-CT detected simultaneous integrated boost. Radiother Oncol 93:213-219
24. Pinkawa M, Holy R, Piroth MD, Klotz J, Nussen S, Krohn T et al (2010) Intensity-modulated radiotherapy for prostate cancer implementing molecular imaging with 18F-choline PET-CT to define a simultaneous integrated boost. Strahlenther Onkol 186:600-606
25. Poulsen MH, Bouchelouche K, Gerke O, Petersen H, Svolgaard B, Marcussen N et al (2010) [18F]-fluorocholine positron-emission/computed tomography for lymph node staging of patients with prostate cancer: preliminary results of a prospective study. BJU Int. 106:639-643
26. Reske SN, Blumstein NM, Glatting G (2008) [11C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging 35:9-17
27. Roberts SG, Blute ML, Bergstralh EJ, Slezak JM, Zincke H (2001) PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc 76:576-581
28. Schillaci O, Calabria F, Tavolozza M, Caracciolo CR, Agrò EF, Miano R et al (2012) Influence of PSA, PSA velocity and PSA doubling time on contrast-enhanced (18)F-choline PET/CT detection rate in patients with rising PSA after radical prostatectomy. Eur J Nucl Med Mol Imaging 39:589-596
29. Schmid DT, John H, Zweifel R et al (2005) Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology 235:623-628
30. Vees H, Buchegger F, Albrecht S, Khan H, Husarik D, Zaidi H et al (2007) (18)F-choline and/or (11)C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy. BJU Int 99:1415-1420
31. Würschmidt F, Petersen C, Wahl A, Dahle J, Kretschmer M (2011) [18F]fluoroethylcholine-PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodes. Radiat Oncol 44:1-8
32. Zeisel SH (1981) Dietary choline: biochemistry, physiology, and pharmacology. Annu Rev Nutr 1:95-121